Introduction
In 2012, 9.3% of Americans or 29 million people had diabetes (National Diabetes Statistics Report, 2014) . The prevalence of diabetes will increase by 366 million people worldwide by 2030; with the population at risk of blindness escalating with increased diabetes incidence, according to World Health Organization (WHO).
The molecular mechanisms of diabetic retinopathy remain poorly understood with extensive investigations ongoing focusing on the cellular pathways underlying hyperglycemic-induced retinal damage and diabetic retinopathy, with the goal of development of novel strategies for therapeutics. miRNA regulate target genes by binding to 3 0 UTR of mRNA, inducing post-transcriptional reduction in gene expression (Olena & Patton, 2010) . miRNA can be detected in serum, plasma, and a variety of body fluids, including saliva and urine (Cortez & Calin, 2009; Igaz & Igaz, 2015) . Thus, miRNA are novel and powerful candidates for diagnostic biomarkers and for assisting in the development of therapeutic strategies (McClelland & Kantharidis, 2014) . Altered expressions of miRNA have been reported in a variety of pathological conditions, including diabetic retinopathy (Sun et al., 2013; Xiong et al., 2014) and inflammatory responses (Ichii et al., 2012; Sonkoly, Stahle, & Pivarcsi, 2008) .
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Abbreviations: miR, microRNA; REC, retinal endothelial cells; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; IL-6, interleukin-6; sIL-6R, soluble interleukin-6 receptor; mIL-6R, membrane-bound interleukin-6 receptor; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor; ADAM-10 and -17, a disintegrin and metalloproteinase domain-10, and -17. There is increasing evidence of the functions of miRNA in many diseases, we still have a limited understanding on how specific miRNA may influence the molecular mechanisms in the pathology of diabetic retinopathy. miR-146a is one of many candidates, in addition to miR-15b-, -16, -18b, -29, -195, and -200b, -221 , that have been studied for a regulatory role in diabetic retinopathy and/or hyperglycemia (Cao, Feng, Chen, Chu, & Chakrabarti, 2014; Cowan et al., 2014; Fulzele et al., 2015; Li et al., 2009; Lin et al., 2016; Mortuza, Feng, & Chakrabarti, 2014; Wu et al., 2016; Ye & Steinle, 2015) . In addition to diabetic retinopathy, miR-146a has been studied in different types of ocular disorders, such as corneal disease (Funari et al., 2013) , age-related macular degeneration (Menard et al., 2016) , uveal melanomas (Ragusa et al., 2013) , autoimmune uveo-retinitis (Watanabe, Keino, Kudo, Sato, & Okada, 2016) , and Graves' ophthalmopathy (Li, Du, Jiang, & He, 2014) . In diabetic retinopathy, reduced levels of miR-146a were found in the serum of T2D patients, which was associated with chronic inflammation (Baldeon et al., 2014) . Also, modified rhythmic expression of miR-146a was shown in human retinal endothelial cells from diabetic donors (Wang et al., 2014) . Our previous study demonstrated inhibitory roles of miR-146a on high glucose-induced TLR4 signaling leading to altered NF-jB and TNFa in REC (Ye & Steinle, 2016) .
Elevated IL-6 levels, a key pro-inflammatory cytokine, have been reported in diabetic retinopathy (Canataroglu et al., 2005; Koskela, Kuusisto, Nissinen, Savolainen, & Liinamaa, 2013; Yoshida et al., 2015) . IL-6 was reported as a potential target of miR-146a, as shown by the homology between the 3 0 -UTR of human IL-6 mRNA and miR-146a (Wu et al., 2013) . Negative regulatory effects of miR146a on IL-6 were reported in patients with T2DM (Balasubramanyam et al., 2011) and in human aortic endothelial cells (Wu et al., 2013) . Classic IL-6 signaling works through membrane bound IL-6 receptors, which is found on only limited types of cells, including subsets of leukocytes, epithelial cells, and hepatocytes (Rose-John, 2012) . It is suggested that IL-6 trans-signaling, acting through soluble IL-6 receptor (sIL-6R), plays a role in the pathophysiology of diabetic retinopathy. Elevated levels of IL-6 and sIL-6R were shown in the serum and aqueous humor of subjects with diabetic retinopathy (Chen, Zhang, Liao, & Wen, 2016) . In addition, higher levels of sIL-6R were found in the serum and vitreous fluid of patients with proliferative DR. Furthermore, the levels of sIL-6R had a significant correlation with VEGF levels in the vitreous fluid .
IL-6 can stimulate Jak/STAT3 signaling in the eye (Elsaeidi, Bemben, Zhao, & Goldman, 2014; Fasler-Kan et al., 2013; Samardzija et al., 2006) . Additionally, high glucose can stimulate STAT3 phosphorylation in retinal endothelial and RPE cells (Chen et al., 2012; Li et al., 2012; Zheng et al., 2010) . The activation of STAT3 plays a role in inflammatory pathways and can initiate ER stress under high glucose conditions in TR-iBRB cells (Chen et al., 2012) . Moreover, IL-6-induced STAT3-mediated nitric oxide resulted in apoptosis (Oh, Lee, Park, & Jun, 2011) . Phosphorylation of STAT3 played a mediatory role in retinal neuronal apoptosis in streptozotocin (STZ)-diabetic rats Li et al., 2011 . Additionally, STAT3-induced apoptosis was mediated through the downregulation of PI3K-Akt pathway in mammary epithelial cells (Abell et al., 2005) and through Bcl-2/Fas signaling in cerebral ischemia/ reperfusion (Guo, Yin, Zi, & Yan, 2016) .
Vascular endothelial growth factor (VEGF), one downstream effector of the STAT3 pathway, is a crucial factor in diabetic retinopathy, mediating increased vascular permeability and pathological angiogenesis (Witmer, Vrensen, Van Noorden, & Schlingemann, 2003) . Upregulation of VEGF mediated by STAT3 has been shown in bovine retinal capillary endothelial cells under high glucose conditions (Zheng et al., 2010) . In addition, the proliferation of endothelial cells induced by VEGF was inhibited when STAT3 was reduced in HUVEC and human retinal microvascular endothelial cells (Wang et al., 2014) . A stimulatory role of VEGF on cell death was shown in mouse cerebral endothelial cells after oxygen-glucose deprivation (Narasimhan, Liu, Song, Massengale, & Chan, 2009) .
Understanding cell type-and disease-specific functions of miR146a is crucial for development of potential therapeutics for clinical application in diabetic retinopathy. In the present study, we tested the hypothesis that elevated levels of miR-146a suppress IL-6 signaling to inhibit pro-inflammatory pathways of STAT3 and VEGF, leading to the prevention of REC apoptosis in high glucose conditions.
Materials and methods

Cell culture
Human REC were cultured as described in our previous study (Ye & Steinle, 2015) . Briefly, REC were purchased from Cell Systems Corporation (CSC, Kirkland, WA). Cells are grown in Cell Systems Medium. Microvascular growth supplement (MVGS, Invitrogen), 10 lg/mL gentamycin, and 0.25 lg/mL amphotericin B are added to all cell cultures. Cells are maintained in normal (5 mM) glucose or transferred to high glucose medium (25 mM) (Cell Systems) for 3 days. Only primary cells within passage 5 were used. Cells were quiesced by incubating in the appropriate medium without growth supplementation for 20 h before the experiments.
Cell transfection with microRNA-mimics and IL-6 siRNA
REC transfection was performed using the miRNA mimic (hsa-miR-146a-5p) (Invitrogen, Carlsbad, CA) or IL-6 siRNA (Dharmacon, Lafayette, CO) using oligofectamine (Invitrogen), following manufacturer instructions. We transfected cells for 48 h before the cell harvest. A final concentration of 50 nM was used for the mimic, with a negative control for all studies with equal concentration of the mimic negative control (Invitrogen) in REC grown in high glucose. For studies with human IL-6 siRNA, a final concentration of 20 nM was used and a negative control group was used for all studies using an equal concentration of a scrambled siRNA (Dharmacon, Lafayette, CO) in REC grown in high glucose. Mock-treated controls, normal glucose (NG) and high glucose (HG), were treated with oligofectamine only.
Real-time quantitative PCR
Total RNA was isolated and purified using the Trizol method. Purity and quantity of RNA was measured using a Synergy HTX multi-mode reader (BioTek; Winooski, VT). For polyA tail reverse-transcriptase PCR, 5 lg of total RNA was treated with DNase I for 15 min at room temperature (Promega; Madison, WI) followed by the addition of polyA using (polyA) polymerase (NEB; Ipswich, MA) at 37°C for 1 h. The final reaction mixtures were extracted with phenol/chloroform, precipitated with isopropanol, and re-dissolved in 25 ll diethylpyrocarbonate (DEPC)-treated water. PolyA-tailed RNA (6 ll) was reversetranscribed into first-strand cDNA using Superscript II reverse transcriptase (Invitrogen) with the oligo-dT adapter primer 5 0 GC GAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN3 0 . For PCR, 1 ll of RT product was diluted three times and used as a template in each reaction. Sequences of primer pairs used to detect human IL-6R (Life Technologies, Carlsbad, CA) were as follows (47): 1) mIL-6R, fwd: 5 0 -CTCCTCTGCATTGCCATTGT-3 0 , rev: 5 0 -TGT GGCTCGAGGTATTGTCA-3 0 , and 2) s-IL6R, fwd: 5 0 -CGACAAGCCTCC CAGGTTCA-3 0 , rev: 5 0 -CGGTTGTGGCTCGAGGTATT-3 0 . GAPDH (OriGene, Rockville, MD) was used as the internal control. SYBR-Green-based real-time PCR was performed using a CFX Connect PCR system (BioRad; Hercules, CA). The relative expression of miRNA was calculated based on the formula: 2 (ÀDelta Delta Ct) . Delta-Delta Ct values are Delta Ct exp. À Delta Ct cont. .
Western blot analysis
As described in our previous study (Ye & Steinle, 2015) , REC were rinsed with cold PBS, collected in lysis buffer containing protease and phosphatase inhibitors, and scraped into tubes. Equal amounts of protein were separated on precast tris-glycine gels (Invitrogen, Carlsbad, CA), and then blotted onto a nitrocellulose membrane. After blocking in TBST (10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5% (w/v) BSA, the membrane was treated with appropriate primary antibodies followed by incubation with secondary antibodies labeled with horseradish peroxidase. Antigen-antibody complexes were detected by chemilluminescence reagent kit (Thermo Scientific, Pittsburgh, PA). Primary antibodies used were phosphorylated STAT3 (Tyr705) and total STAT3 (purchased from Cell Signaling, Danvers, MA), VEGF (Abcam, Cambridge, MA), ADAM10, ADAM17 (Santa Cruz Biotechnology, Dallas, TX), and beta actin (Santa Cruz, Santa Cruz, CA).
ELISA analysis
A human IL-6 ELISA (Thermo Fisher scientific, Grand Island, NY) was used to measure levels of the pro-inflammatory cytokine, IL-6, in cell lysates. Equal protein was loaded (100 lg) into all wells to allow for comparisons based on O.D. To quantify the levels of cytoplasmic histone-associated DNA fragments, cell death detection ELISA (Roche, Indianapolis, IN) was used. Equal protein was loaded (20 lg) into all wells to allow for comparisons based on O.D. In addition, a human sIL-6R ELISA (Abcam, Cambridge, MA) was used to assess the levels of soluble IL-6 receptors in culture supernatant.
Equal volume of samples was loaded (100 ll) into all wells to allow for comparisons based on O.D. Manufacturer's instructions were followed for all ELISA, except extended incubation of samples and antibody reagents overnight at 4°C.
Statistics
Data were statistically analyzed using Prism software (GraphPad, La Jolla, CA). Analyses were done using unpaired Student t test with two-tailed p value. p < 0.05 was considered significant. Data are presented as mean ± SEM. For Western blots, a representative blot is presented.
Results
miR-146a reduced IL-6 levels in high glucose conditions
Our previous study demonstrated that exposure to high glucose decreased miR-146a expression in REC, and we confirmed the elevated levels of miR-146a after transfection using miRNA mimic by qRT-PCR (Ye & Steinle, 2016) . As a negative correlation of miR146a and IL-6 was shown in patients with T2DM (Balasubramanyam et al., 2011) and in human aortic endothelial cells (Wu et al., 2013) , thus, we aimed to determine whether miRNA-146a affected IL-6 levels in REC under high glucose conditions. We performed transfections with miR-146a mimics to increase miRNA expression to study downstream signaling pathways. REC were transfected with mimic, miR-146a-5p at a final concentration of 50 nM for 48 h. We demonstrated that miR146a overexpression resulted in a significant decrease of IL-6 levels in high glucose conditions (Fig. 1) . That suggests that miR-146a may directly or indirectly target IL-6, and that IL-6 is a target pathway affected by miR-146a in REC.
miR-146a inhibited STAT3 activation in high glucose conditions
It has been reported that the IL-6 family stimulates Jak/STAT3 signaling in the eye (Elsaeidi et al., 2014; Fasler-Kan et al., 2013; Samardzija et al., 2006) . Also, high glucose can stimulate STAT3 phosphorylation in retinal endothelial and RPE cells (Chen et al., 2012; Li et al., 2012; Zheng et al., 2010) . Thus, we investigated whether miR-146a regulated levels of STAT3 phosphorylation in REC under high glucose conditions. Our results showed that high glucose significantly increased the phosphorylation of STAT3. However, the elevated levels of STAT3 activation were reduced by miR-146a overexpression under high glucose conditions (Fig  2) . We, therefore, demonstrated that miR-146a plays a regulatory role in suppressing STAT3 activation in REC in high glucose.
miR-146a decreased the levels of VEGF expression
As STAT3 plays a role as an upstream effector to VEGF in retinal endothelial cells (Wang et al., 2014; Zheng et al., 2010) , we examined whether VEGF levels could be altered in response to the increase of miR-146a and decreased STAT3. Our results demonstrated that high glucose culturing conditions significantly increased VEGF levels compared to cells in the control NG group. However, miR-146a overexpression resulted in the suppression of VEGF levels in HG (Fig. 3) . Therefore, this suggests that elevated levels of miR-146a induced a significant decrease of VEGF levels, likely mediated through the reduction of STAT3 phosphorylation.
miR-146a reduced apoptosis in high glucose conditions
Next, we examined whether miR-146a can protect REC from apoptosis, which may be caused by high glucose-induced proinflammatory signaling. Previous studies have shown mediatory role of STAT3 signaling (Abell et al., 2005; Guo et al., 2016; Li et al., 2011; Oh et al., 2011) and VEGF (Narasimhan et al., 2009) in inducing cellular apoptosis, and our results demonstrated inhibitory role of miR-146a on the phosphorylation of STAT3 and VEGF levels in REC. To examine the effects of increased levels of miR-146a on apoptosis, we examined DNA fragmentation of REC under high glucose conditions. Our results demonstrated that overexpression of miR-146a significantly reduced DNA fragmentation levels in REC cultured in high glucose (Fig. 4) . These results suggest that miR-146a can protect REC from high glucose-induced apoptosis, potentially through inhibition of pro-inflammatory pathways.
The regulatory role of miR-146a was mediated by IL-6 signaling in REC
Then, we examined whether IL-6 acts as a mediator in the regulatory process of miR-146a on pro-inflammatory signaling in REC. REC were transfected with human IL-6 siRNA at a final concentration of 20 nM for 48 h. We demonstrated that both IL-6 and sIL-6R levels were increased in REC under high glucose conditions and the expression was suppressed following IL-6 siRNA treatment (Fig. 5  A and B) . That indicates that IL-6 signaling plays a role in REC as a molecular mechanism underlying high glucose conditions. We also demonstrated that STAT3 phosphorylation and VEGF levels were significantly reduced following inhibition of IL-6 signaling ( Fig. 5 C and D) . The suppression of IL-6 signaling prevented REC apoptosis, as shown with decreased levels of DNA fragmentation (Fig. 5E) . The results suggest that IL-6 plays a role in the upregulation of STAT3/VEGF pathway and apoptosis, via binding to sIL-6R in REC under high glucose conditions. Human s-IL-6R protein can be generated by either alternative splicing or proteolytic cleavage of membrane-bound IL-6R (Briso, Dienz, & Rincon, 2008; Li, Rokavec, & Hermeking, 2015) . To demonstrate IL-6 signaling in a direct approach, we examined the levels of membrane-bound IL-6R (mIL-6R) and soluble IL-6R (sIL-6R) using RNA isolated from REC by real-time quantitative PCR (Table 1) . We demonstrated that the expression of sIL-6R was significantly increased in HG when compared to NG. REC treated with IL-6 siRNA showed significantly reduced levels of sIL-6R than high glucose only (Table 1 ). The overexpression of miR-146a did not change sIL-6R expression compared to high glucose only (Table 1) . Additionally, we assessed the levels of ADAM10 and ADAM17, the sheddases of IL-6R, which can generate sIL-6R proteolytically from the membrane-bound form in humans (Garbers et al., 2011) . We showed that the levels of ADAM10/and 17 were not changed in different culturing conditions ( Fig. 6A and B) . The results suggest that sIL-6R was produced in human REC via alternative splicing of mIL-6R under high glucose conditions.
Discussion
Our knowledge of the molecular and cellular mechanisms by which miRNA function in diabetic retinopathy is still limited and additional studies are required to develop novel therapeutics for diabetic retinopathy. So far, only a small number of studies have been performed to reveal the relation of miR-146a in pathological processes of diabetic retinopathy. Predominantly, miR-146a has been implicated as an epigenetic regulator of inflammatory responses. The regulatory roles of miR-146a that affects inflammatory pathways have been shown in various cell types, including human RPE cells (Kutty et al., 2013) , trabecular meshwork cells (Li, Luna, Qiu, Epstein, & Gonzalez, 2010) , brain endothelial cells (Wu et al., 2015) , brain microglical cells (Sharma, Verma, Kumawat, Basu, & Singh, 2015) , and cells from intervertebral discs (Gu et al., 2015) . Much work has demonstrated that REC are an important cell type substantially affected in diabetic retinopathy (Du, Miller, & Kern, 2003; Du, Smith, Miller, & Kern, 2002; Kowluru, Kowluru, & Kanwar, 2007) . Since the expression and functions of miRNA are specific to the type of cell, tissue, and disease, condition-specific examinations are critical to get clear understanding on the regulatory networks between miRNA and their associated molecular pathways. Some studies have reported that miR-146a plays a pro-inflammatory role in the retina and diabetic retinopathy. In human RPE cells, miR-146a expression was IL1b-dependent and the miRNA expression was significantly increased by the addition of the mixture of IFN-c, TNFa, and IL1b in culture (Kutty et al., 2013) . Additionally, a negative regulatory role of miR-146a on the levels of IRAK1 and ICAM-1 was shown in human REC (Wang et al., 2014) . Our recent study demonstrated that miR-146a inhibited TLR4, NF-jB, and TNFa in REC grown in high glucose (Ye & Steinle, 2016) . However, it is highly likely that miR-146a regulates a number of pro-inflammatory pathways key to diabetic retinopathy. In this study, we examined the effects of miR-146a regulation on pro-inflammatory and survival/apoptotic pathways in REC cultured in high glucose. Our results provide novel clues to the inhibitory role of miR-146a on STAT3/VEGF pathway through IL-6 signaling in high glucoseinduced diabetic retinopathy. We previously showed that high glucose induced a significant decrease in miR-146a expression in REC (Ye & Steinle, 2016) . Thus, in this study we induced the overexpression of miR-146a using miR146a mimics in REC under high glucose conditions to examine the roles in IL-6/STAT3/VEGF signaling. Our data demonstrated that overexpression of miR-146a reduced IL-6 levels in high glucose conditions, suggesting that miR-146a may inhibit IL-6 in REC in high glucose. Consistent with our results, a negative correlation of miR-146a expression with IL-6 levels was demonstrated in human aortic endothelial cells in vitro (Wu et al., 2013) and patients with T2DM (Balasubramanyam et al., 2011) . IL-6 can stimulate Jak/STAT3 signaling in the eye (Elsaeidi et al., 2014; Fasler-Kan et al., 2013; Samardzija et al., 2006) . Activation of STAT3 pathway plays a role in high glucose-induced endoplasmic reticulum stress and contributes to endothelial inflammation in the retina of Type 1 diabetes (Chen et al., 2012) . Our results demonstrated that increased levels of STAT3 phosphorylation were reduced by miR-146a overexpression in high glucose conditions. This suggests that increased levels of STAT3 phosphorylation in high glucose conditions are decreased by miR-146a-driven suppression of IL-6.
De novo synthesis of sIL-6R has been shown in human B cells (Korholz et al., 1994) . Our qPCR results showed a significant elevation of sIL-6R expression under HG conditions with no changes in ADAM10 or ADAM17 levels was found between culture conditions, suggesting that de novo synthesis of sIL-6R occurred in REC through alternative splicing of mIL-6R to induce IL-6 signaling. miR-146a overexpression in REC did not result in decreased expression of mIL-6R and sIL-6R in HG. It is possible that miR146a regulated other unknown signaling pathways and that, in turn, could counterbalance the inhibitory effects of miR-146a on IL-6 signaling. We will explore these other pathways in future studies.
It has been reported that inhibition of the STAT3 pathway decreases VEGF expression (Li et al., 2012; Wang et al., 2012; Zheng et al., 2010) . Our results demonstrated that miR-146a overexpression decreased the levels of VEGF protein, in addition to STAT3 phosphorylation. Our findings of reduced VEGF by miR146a are consistent with other studies as reported in HUVECs (Halkein et al., 2013) and in a nude mouse model (Xu et al., 2012) . Therefore, the reduction of STAT3 and VEGF by miR-146a may have a therapeutic potential as a molecular target and genetic regulatory element for treating angiogenic disorders.
Previous studies have shown STAT3-induced apoptosis in the retina of diabetic rats (Li et al., 2011) , IL-6-treated beta cells (Oh et al., 2011) , focal cerebral ischemia/reperfusion rats (Guo et al., 2016) , and mammary gland involution (Abell et al., 2005) . VEGF also played a role on inducing endothelial cell death after oxygen-glucose deprivation (Narasimhan et al., 2009 ). Our previous studies (Jiang, Zhang, Soderland, & Steinle, 2012; Panjala & Steinle, 2011; Williams & Steinle, 2009; Ye & Steinle, 2015; Zhang & Steinle, 2013) and many others (Nahomi, Palmer, Green, Fort, & Nagaraj, 2014; Safi, Qvist, Yan, & Ismail, 2014; Zhang, Zhang, & Liang, 2016) have demonstrated that high glucose increased the levels of apoptosis in REC. We showed that miR146a played a role in reducing REC apoptosis under high glucose conditions by decreasing the levels of DNA fragmentation. Finally, we demonstrated that the regulatory role of miR-146a on pro-inflammatory pathway and apoptosis was mediated by IL-6 signaling in REC under high glucose conditions. That suggests that miR-146a can protect REC from high glucose-induced apoptosis, potentially through the suppression of the STAT3/VEGF pathway via IL-6 signaling.
Conclusions
Taken together, our study demonstrated that elevated expression of miR-146a resulted in inhibition of STAT3 and VEGF signaling through IL-6 signaling in REC under high glucose conditions. Therefore, we present a potential regulatory mechanism whereby miR-146a can downregulate IL-6-mediated STAT3/VEGF signaling, resulting in reduced apoptosis in REC. The outcome suggests that miR-146a is a potential therapeutic target for rescuing diabetic retina through the inhibition of pro-inflammatory pathways of IL-6/STAT3/VEGF.
